["{\"step_by_step_thinking\": \"Tyrosine kinases have been associated with cancer, and tyrosine kinase inhibitors are being developed as potential anticancer drugs. As mentioned in the 'Tyrosine Kinase Inhibitors' document, it is likely that these inhibitors will enter clinical trials in cancer patients. Saracatinib is a type of tyrosine kinase inhibitor, which means it has been tested for its potential use as an anticancer drug. Clinical trials are necessary to evaluate the efficacy and safety of any new treatment. Therefore, based on this information, it can be concluded that saracatinib has been tested in clinical trials.\", \"answer_choice\": A}"]